FUROSCIX
Peakfurosemide injection 80 mg/ 10 ml
NDASUBCUTANEOUSSOLUTION
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
FUROSCIX (furosemide injection 80 mg/ 10 ml) is 12. Approved for edema in pediatric patients weighing 43 kg, above, chronic kidney disease and 1 more indications. First approved in 2022.
Drug data last refreshed 7m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROSCIX is a subcutaneous furosemide injection (80 mg/10 mL) approved in October 2022 for treating edema in pediatric patients ≥43 kg and those with chronic kidney disease including nephrotic syndrome. It is a loop diuretic that inhibits sodium and chloride reabsorption in the proximal and distal tubules and loop of Henle, producing diuresis with bioavailability equivalent to intravenous administration (99.6%).
$0.009BPart D
Peak7.8 years to LOEEarly-stage commercial product in peak growth phase with modest Part D uptake (1,783 claims in 2023); brand team size likely limited but growing.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.